ALKERMES PATHWAYS RESEARCH AWARDSSM

Alkermes Pathways Research Awards supports research of central nervous system disorders and addiction

About Pathways

With millions of people impacted by central nervous system (CNS) disorders, more research is urgently needed to bring relief to those who are suffering. The ALKERMES PATHWAYS RESEARCH AWARDSM program is designed to support the next generation of researchers who are working on the front-lines to advance our understanding and awareness of CNS disorders, including addiction.

The annual Pathways program provides funding for up to four research projects with an individual grant amount of up to $100,000 per project.

Recipients are selected by an independent review committee through a competitive review process, and research is funded by Alkermes.

Click here for information regarding eligibility and selection criteria.

2018 Pathways Research Awards

In its inaugural year (2018), the ALKERMES PATHWAYS RESEARCH AWARDSSM program supported projects focused on substance use disorder, a public health crisis.

With an estimated 1 in 7 people in the United States developing a substance use disorder in their lifetime, and related mortality rates rising rapidly, there is an urgent need to discover innovative approaches to improve prevention, increase understanding, advance treatment, and enhance public awareness of substance use disorders.

2018 Recipients

  • Lais Fernanda Berro, Ph.D., University of Mississippi Medical Center, for preclinical research on quantitative pharmacology and pharmacotherapeutics for opioid and benzodiazepine co-abuse
  • Derek Blevins, M.D., Columbia University, New York State Psychiatric Institute, for evaluating the effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of chronic pain in patients currently treated with prescription opioids who are at risk of developing a moderate or severe opioid use disorder
  • Mehdi Farokhnia, M.D., Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), for examining the neurobiological correlates and safety and efficacy of the GLP-1 system in relation to alcohol use
  • Sarah L. Withey, Ph.D., Harvard Medical School, McLean Hospital, for assessing the effects of continuous exposure to naltrexone on the behavior and reward circuitry involved in opioid addiction relapses in non-human subjects

2019 Pathways Research Awards

The application period for the 2019 Pathways awards will open on April 1, 2019 and the deadline for submissions will be July 31, 2019.

Questions?

Please contact info@PathwaysResearchAwards.com.